increas clariti strength
franchis pt
regeneron stock good run sinc pt upgrad earli
ytd vs nbi attribut strong perform due competitor
stumbl core eylea franchis nv beovu case retin vascul
lead greater certainti eylea growth beyond see exhibit
strengthen dupix sale partner sanofi increas ex-u commit
greater certainti around cost-control restructur antibodi agreement
sanofi qualiti intern gener pipelin go strength strength
potenti materi catalyst adjust sales/earn
upward updat pt stay bullish
beovu launch telegraph blockbust opportun howev like
potenti eylea killer past year beovu could met
earli demis potenti blockbust statu tandem report best
eylea quarter sinc product launch y/i quarterli growth
averag better sale higher
eylea number like conserv follow reason rapid
growth dme segment eylea us sale vs earli
dme could grow high vs wamd high singl digit full suppli pre-
fill eylea syring market consolid eylea domin
statu market share brand anti-vegf
dupix continu surpris upsid meet surpass
launch expect dupix us sale continu constitut
total sale ex-u sale grew torrid growth current annual
mostli atop dermat account increas indic
asthma allerg condit age access geograph roll-
ex-u dupix strength flatter sanofi collabor revenu
consist note screen well sales/earn
momentum second behind large-cap biotech best-in-class
pipelin limit upcom brand biosimilar competit brand
gener alreadi exist compound avastin core eylea howev
laggard margin among peer-group see recent stock
perform seem correl earn sale momentum
ytd also affect treatment develop
believ street increasingli focus strength core franchis
potenti moder opex guidanc call sanofi agreement
re-structur final modestli adjust believ
upsid near/mid-term sales/earn number
year price histori
base biopharmaceut compani
eye
diseas high cholesterol
also best-in-class
analyst certif import disclosur see disclosur
praluent litig continu binari outcom remov
dupilumab cemiplimab launch ramp line expect
abl minim margin contract slow
eylea growth cost launch dupixent/kevzara/praluent/
abl maintain adjust gm
patent issu either dupix kevzara
patient demonstr potenti uncommon sae
cusp strong sale growth
increas eylea penetr dme approv
launch fast uptak dupix asthma/oth allerg
condit approv launch fast uptak libtayo
potenti slow believ could follow
left jab acceler sale right hook oper
restructur antibodi agreement sanofi
pdufa dupix atop dermat pediatr
potenti file late-stag lymphoma libtayo
readout nsclc
adjust oper margin current get
dupilumab ad/asthma sarilumab launch progress
rapidli anticip
eylea penetr dme npdr bolster
sale growth mitig eventu wamd market share loss
praluent patent rule favor sale rebound faster
antibodi cemiplimab sale cscc
top-lin revenu shrink due slow eylea growth creat near-
term margin pressur new product launch
eylea competit make signific inroad core franchis
launch product dupix demonstr uncommon sae
price target employ composit valuat methodolog biotech compani util forward p/
 multipl npv adjust non-gaap estim earn sinc sector typic high-growth/high-expect aim
rank target compani base qualiti sale and/or earn growth vs peer group peer index nbi
expect earn growth next three five year expect higher termin
multipl adj ep due greater certainti qualiti sales/earn growth appli discount rate
vs peer group averag
risk includ slower expect eylea growth and/or continu opex increas creat near-term margin pressur slower
expect new product launch eylea competit risk regulatori delay non-approv emerg unexpect side effect
number other non-large-cap growthgross margin net incom ep growth outperform
revenu eylea product us cemiplimab collabor healthcar collabor licens outperform
statement million except per product sanofi collabor bayer healthcar collabor technolog licens total research sell gener good collabor contract total oper adjust incom adjust invest interest loss extinguish debt- incom incom incom tax expense- adjust net non-gaap dilut dilut share adjust comp gross oper incom tax outperform
npv cagrcommentstot revenu growth ebitda growth net incom growth y/i growth tax rate us adj ep compound-annual-growth-rate group index nbi indexp group adj ep compound-annual-growth-rate expect nbi index ep ltgpeer group termin price-to-earnings multipl multipl large-cap peer group opco estim us termin price-to-earnings multipl peer group sale ep growth upsidetermin valu us wacc peer group averag per bloomberg us discount rate adj ep price-to-earnings valuat outperform
stock price compani mention report
